Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

Overview of attention for article published in Diabetes, Obesity & Metabolism, April 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source
twitter: 2 X users

patent: 2 patents

Citations

dimensions_citation: 102 Dimensions

Readers on

mendeley: 139 Mendeley

Summary Policy documents X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

Therapeutic uses of dulaglutide

Grant US-11890325-B2

United States of America

Methods of using and compositions containing dulaglutide

Grant US-11576950-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.